PCP (Phencyclidine)

Dose, frequency, and chronicity dominate PCP detection windows. A single occasional exposure typically clears immunoassay detection within 7 to 14 days. Chronic, heavy use produces saturation of adipose tissue stores; PCP then redistributes slowly back into plasma and continues to be excreted in urine for weeks after the last exposure. Detection of 30 days or more in chronic users is well documented in the toxicology literature and is the principal reason a persistent low-level positive in substance-use treatment should be interpreted with the patient's use history in mind rather than assumed to reflect new exposure.

Route of administration affects onset and peak plasma levels but has a smaller effect on total detection window than dose and frequency. Smoking PCP-treated material produces rapid onset (minutes) and high peak plasma concentrations; oral ingestion produces slower onset (30 to 60 minutes) and lower peaks at the same total dose; intranasal and intravenous routes produce intermediate profiles. Across all routes, the lipophilic distribution into fat is what governs the prolonged elimination tail.

Hepatic metabolism by CYP3A4 and CYP2B6 is the principal clearance pathway, producing hydroxylated metabolites that are conjugated and excreted in urine. CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) can shorten the window; inhibitors (ritonavir, ketoconazole) can extend it modestly. Hepatic impairment from cirrhosis, hepatitis, or other causes prolongs clearance. Urinary pH also matters: PCP is a weak base, and acidic urine increases ionized PCP and accelerates renal excretion, while alkaline urine slows it; this is occasionally relevant in critical-care management of acute PCP intoxication.

Body composition contributes meaningfully because of PCP’s lipophilicity. Individuals with higher adipose mass store proportionally more PCP and have correspondingly longer elimination tails — a clinically important consideration for substance-use treatment programs assessing patients with high BMI, where a persistently positive screen weeks into abstinence is consistent with redistribution rather than relapse. Age, sex, and genetic variation in CYP enzymes contribute smaller modifying effects. Pregnancy, renal impairment, and concurrent medications interacting with hepatic enzymes can all shift the window in either direction. Perinatal exposures are documented in toxicology literature and matter for hospital-based maternal–neonatal screening programs, where both maternal and infant urine may be tested under state child-welfare reporting frameworks. As with other analytes, dilute urine (low creatinine, low specific gravity) reduces the apparent concentration without changing the actual amount excreted, which is why specimen validity testing accompanies every SAMHSA-style screen.

PCP is one of the five analytes in the SAMHSA Mandatory Guidelines panel (the SAMHSA-5), alongside marijuana, cocaine, amphetamines, and opiates. The mandatory federal cutoff for PCP in urine is 25 ng/mL for the initial immunoassay screen and 25 ng/mL for confirmation by GC-MS or LC-MS/MS. These cutoffs apply to all DOT-regulated workplace testing, federal-employee testing under HHS rules, and any program that has adopted SAMHSA-style procedures by contract or policy.

Industry-standard commercial immunoassays generally match the SAMHSA cutoff at 25 ng/mL urine, which is the cutoff used on Magenta's 12-, 13-, and 17-panel cups and on the 10-panel CLIA-waived dip card. Some non-federal devices offer alternative cutoffs (10 ng/mL for higher-sensitivity applications), but the 25 ng/mL standard is the default for clinical and workplace use. Magenta panels that include PCP screen at the SAMHSA cutoff and are appropriate for both federally regulated and non-regulated programs.

Oral-fluid and hair cutoffs differ from urine and are device-specific. SAMHSA published Mandatory Guidelines for federal oral-fluid testing in 2019 (effective 2020) with a PCP cutoff of 10 ng/mL screen and 10 ng/mL confirmation. SAMHSA Mandatory Guidelines for hair testing have been proposed but were not finalized as of this writing; programs using hair for PCP should follow the device manufacturer’s cutoff and use SAMHSA-certified laboratory confirmation. Programs should match the device cutoff to the regulatory framework they operate under and document the cutoff used on every result.

Operationally, the gap between an initial presumptive positive immunoassay and the GC-MS or LC-MS/MS confirmation is where most programs experience friction. Under SAMHSA-style procedures, no adverse action is taken on a presumptive positive alone — the specimen is forwarded under chain-of-custody to a SAMHSA-certified laboratory, the laboratory confirms or refutes the screen at the 25 ng/mL cutoff, and a Medical Review Officer then contacts the donor to inquire about medication history, prescription dextromethorphan products, and other potential cross-reactant exposures before reporting the verified result. For DOT-regulated employers, that workflow is non-negotiable; for non-regulated workplace and clinical programs, replicating it is best practice and substantially reduces the risk of disputed actions on what would otherwise be cross-reactant artefacts.

PCP urinary immunoassays use the same lateral-flow competitive-binding format as the other analytes on Magenta's multi-panel cups and dip cards. The PCP antibody is raised against the phencyclidine molecule itself and produces a positive result above the device cutoff. Read times are typically five minutes, and the interpretation rules are identical to other analytes: a visible test line indicates a negative result, absence of a test line indicates a presumptive positive at or above the cutoff, and absence of the control line invalidates the test and requires recollection.

False positives are the principal interpretive issue for PCP immunoassays. Dextromethorphan — a common over-the-counter cough suppressant — is the most frequently cited cross-reactant; ingestion of recommended doses can produce immunoassay-positive results that resolve on confirmation testing. Venlafaxine (Effexor) and its active metabolite O-desmethylvenlafaxine cross-react on several PCP immunoassays at therapeutic plasma concentrations and have been documented as a recurring source of false positives in psychiatric and primary-care populations. Diphenhydramine (Benadryl) at high doses, doxylamine, and tramadol have all been reported as cross-reactants on specific devices. The clinical implication is straightforward: a presumptive positive PCP screen warrants confirmation by GC-MS or LC-MS/MS before any adverse clinical or employment action, particularly in donors with documented use of these medications.

Ketamine cross-reactivity on PCP immunoassays is variable by manufacturer. Some devices show meaningful ketamine cross-reactivity at high concentrations; others do not. Programs that need to distinguish PCP exposure from ketamine exposure — for example, in pain clinics where ketamine infusions are used or in psychiatric settings using esketamine (Spravato) — should review the device package insert for ketamine cross-reactivity data and order a separate ketamine immunoassay or laboratory confirmation when ambiguity exists.

Confirmation testing by GC-MS or LC-MS/MS is the SAMHSA-required next step for any presumptive PCP positive in a federally regulated program and the recommended next step in any clinical or non-regulated workplace program before adverse action. The confirmatory test quantifies PCP specifically and rules out cross-reactant interference. SAMHSA-certified laboratories perform the confirmation under chain-of-custody. For pharmaceutical patients on medications known to cross-react (dextromethorphan, venlafaxine, diphenhydramine), the Medical Review Officer review of any confirmed positive should incorporate the medication history.

Specimen validity testing accompanies every PCP screen on Magenta panels that include adulterant pads (creatinine, specific gravity, pH, oxidants). Because PCP is lipophilic and slowly excreted, dilute urine can mask a true positive; the validity panel flags suspiciously dilute or adulterated specimens for recollection or further investigation under the program's chain-of-custody policy.